Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zymeworks Inc.
  6. Financials
    ZYME   US98985Y1082

ZYMEWORKS INC.

(ZYME)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
9.580 USD   -1.74%
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 1 7932 171763617617-
Enterprise Value (EV)1 1 4941 929561332301400
P/E ratio -11,9x-13,2x-3,99x-38,2x-7,35x-14,8x
Yield ------
Capitalization / Revenue 60,7x55,7x28,6x2,56x11,6x5,02x
EV / Revenue 50,6x49,5x21,0x1,38x5,68x3,26x
EV / EBITDA -10,2x-10,7x-2,68x-1,86x-1,75x-3,58x
Enterprise Value (EV) / FCF -16,9x-12,4x-2,74x3,39x-1,69x-2,11x
FCF Yield -5,90%-8,07%-36,5%29,5%-59,1%-47,5%
Price to Book 7,32x5,81x3,07x---
Nbr of stocks (in thousands) 39 43845 94646 55464 40964 409-
Reference price (USD) 45,547,316,49,589,589,58
Announcement Date 03/02/202002/24/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 29,539,026,724153,1123
EBITDA1 -146-180-209-178-172-112
Operating profit (EBIT)1 -151-187-216-68,3-110-76,2
Operating Margin -510%-481%-808%-28,4%-206%-62,0%
Pre-Tax Profit (EBT)1 -146-180-212-43,7-116-96,6
Net income1 -145-181-2126,38-116-79,6
Net margin -492%-464%-794%2,65%-218%-64,8%
EPS2 -3,83-3,58-4,11-0,25-1,30-0,65
Free Cash Flow1 -88,2-156-20598,0-178-190
FCF margin -298%-400%-768%40,7%-335%-155%
FCF Conversion 60,4%86,5%98,0%-55,0%104%170%
Dividend per Share2 ------
Announcement Date 03/02/202002/24/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 1,925,442,6321414,14,13
EBITDA -70,2-64,3----
Operating profit (EBIT)1 -72,7-65,8-50,4139-22,2-38,7
Operating Margin -3 794%-1 210%-1 914%64,7%-157%-937%
Pre-Tax Profit (EBT)1 -72,7-64,6-47,9140-21,7-38,2
Net income1 -72,6-64,6-47,8167-21,7-38,2
Net margin -3 790%-1 187%-1 819%77,9%-154%-924%
EPS2 -1,19-0,97-0,722,46-0,58-0,62
Dividend per Share ------
Announcement Date 05/04/202208/04/202211/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 299242202285316217
Leverage (Debt / EBITDA) 2,05x1,34x0,97x1,60x1,84x1,94x
Free Cash Flow1 -88,2-156-20598,0-178-190
ROE (Net Profit / Equities) -68,3%-55,1%-64,3%30,6%-23,5%-21,9%
Shareholders' equity1 21332833020,8493363
ROA (Net Profit / Asset) -47,5%-39,8%-45,7%20,9%-17,1%-15,7%
Assets1 30645346430,5678505
Book Value Per Share 6,218,145,34---
Cash Flow per Share -2,15-----
Capex1 6,324,3112,410,010,510,5
Capex / Sales 21,4%11,1%46,5%4,16%19,8%8,55%
Announcement Date 03/02/202002/24/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 617 041 927
Net sales (USD) 26 680 000
Number of employees 286
Sales / Employee (USD) 93 287
Free-Float 86,5%
Free-Float capitalization (USD) 533 695 803
Avg. Exchange 20 sessions (USD) 9 054 859
Average Daily Capital Traded 1,47%
EPS & Dividend